Open AccessManagement of Retinopathy of Prematurity—Use of Anti-VEGF Therapy
Author(s) -
Kimberly D. Tran,
Linda A. Cernichiaro-Espinosa,
Audina M. Berrocal
Publication year - 2019
Publication title -
asia-pacific journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.163
H-Index - 20
ISSN - 2162-0989
DOI - 10.22608/apo.2017436
Subject(s) - retinopathy of prematurity , medicine , childhood blindness , sedation , blindness , dosing , vascular endothelial growth factor , intensive care medicine , pediatrics , ophthalmology , vegf receptors , surgery , optometry , gestational age , pregnancy , genetics , biology
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. Although laser photocoagulation re-mains the gold standard for treating threshold and prethreshold disease (type 1 ROP), the off-label use of anti‒vascular endothelial growth factor (anti-VEGF) therapy to treat ROP is increasing. Benefits include acute regression of ROP, growth of retinal vasculature beyond the demarcation line, lesser degree of myopia and peripheral visual field loss, and avoidance of sedation and intubation required for laser. However, controversies regarding anti-VEGF in this vulnerable population persist including choice of anti-VEGF agent, dosing, systemic absorption, safety, and late recurrence. This review updates recent evidence regarding the use of anti-VEGF therapy in the management of ROP.